BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2303 related articles for article (PubMed ID: 18191065)

  • 1. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus.
    Danne T
    Clin Ther; 2007; 29 Suppl D():S145-52. PubMed ID: 18191066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; GarcĂ­a-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections.
    ; Nicolucci A; Maione A; Franciosi M; Amoretti R; Busetto E; Capani F; Bruttomesso D; Di Bartolo P; Girelli A; Leonetti F; Morviducci L; Ponzi P; Vitacolonna E
    Diabet Med; 2008 Feb; 25(2):213-20. PubMed ID: 18201210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
    Bolli GB
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness.
    Radermecker RP; Scheen AJ
    Diabetes Metab Res Rev; 2004; 20(3):178-88. PubMed ID: 15133748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB
    Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ; Ligthelm R; Christiansen JS; Liebl A
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin pump therapy and rapid acting insulin: what have we learned?
    Zinman B
    Int J Clin Pract Suppl; 2001 Sep; (123):47-50. PubMed ID: 11594299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: a meta-analysis.
    Monami M; Lamanna C; Marchionni N; Mannucci E
    Exp Clin Endocrinol Diabetes; 2009 May; 117(5):220-2. PubMed ID: 19301231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus.
    Kinsley B
    Clin Ther; 2007; 29 Suppl D():S153-60. PubMed ID: 18191067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
    Bruttomesso D; Bonomo M; Costa S; Dal Pos M; Di Cianni G; Pellicano F; Vitacolonna E; Dodesini AR; Tonutti L; Lapolla A; Di Benedetto A; Torlone E;
    Diabetes Metab; 2011 Nov; 37(5):426-31. PubMed ID: 21474360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
    Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 116.